You are here: Industry Insights > ADC

News List

MSD, BI and CStone Pharmaceuticals Made Significant Investments in ROR1 ADC Far-away from the Crowd
May 06, 2024
Ipsen Invested USD 900 Million to Introduce Sutro Biopharma ADC.
Looking at the ADC Territory of Two Industry Pioneers From the DS-8201 Patent Dispute Yefenghong
January 02, 2024
A study by renowned American economist Edwin Mansfield suggests that 60% of new drugs would not be invented without patent protection, highlighting the importance of patent protection in the pharmaceutical industry today.
A comprehensive review of the currently marketed ADC drugs: the industry maintains high prosperity WND
November 07, 2023
Antibody-drug conjugates (ADCs) are a class of drugs composed of antibodies targeting tumor antigens and a variable number of small molecule toxins linked through connectors.
PD-1 Inhibitor Combined with ADC, the Strong Cooperation of Innovent and Remegen Far-away from the Crowd/PharmaSources
July 25, 2023
Recently, Innovent and Remegen will carry out a clinical research cooperation on the combination of Sintilimab Injection, a PD-1 inhibitor, with RC88, a novel antibody-drug conjugate targeting MSLN, and RC108, a novel ADC targeting c-MET, res.
Summary of Immune Checkpoint Inhibitor Combined with ADC Yefenghong/PharmaSources
July 25, 2023
With the maturity of ADC technology, the combined scheme of IO and ADC is showing a therapeutic potential.
Innovative Drug HER2 ADC Rejected for Marketing, Stricter FDA Review May be Normal in the Future Xiaobin/PharmaSources
June 06, 2023
The FDA's rejection of the marketing of SYD985 is just the beginning, and with the rising enthusiasm for the R&D of ADCs, the standards of subsequent review by the FDA of the popular target ADCs will be inevitably raised.
More ADCs made in China, Led by Kelun Pharmaceutical, Expanding into the World Market with a Total Transaction Amount of over USD 20 billion Yi/PharmaSources
June 06, 2023
More ADCs made in China, led by Kelun Pharmaceutical, expanding into the world market with a total transaction amount of over USD 20 billion.
The Increasing ADC+CDMO Industry Collaboration Yefenghong/PharmaSources
April 19, 2023
Recently, the heat on ADC pipeline deals is around, and the deal sizes are kept refreshing.
ADC vs PDC-- Status Quo of the R&D of ADC-PDC Drug in China and the World PharmaSources/zhulikou431
November 15, 2021
With the sustained investment in China's pharmaceutical industry and the growing attraction of China's pharmaceutical market to global innovative drugs, more projects of innovative drugs have added the listing in China as a necessary part.
A New Target in ADC: Nectin-4 PharmaSources/Yefenghong
September 14, 2021
Recently, the application for clinical trail of Mabwell's ADC drug (9MW2821) targeting Nectin-4 has been accepted by NMPA. It is the first time that domestic enterprise enters the IND stage with the same target drug.